<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Netramark Holdings Inc — News on 6ix</title>
<link>https://6ix.com/company/netramark-holdings-inc</link>
<description>Latest news and press releases for Netramark Holdings Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 22 Apr 2026 11:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/netramark-holdings-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d691bbbeedb30cb6ff0a43.webp</url>
<title>Netramark Holdings Inc</title>
<link>https://6ix.com/company/netramark-holdings-inc</link>
</image>
<item>
<title>NetraMark Positioned to Advance Psychedelic Clinical Trials Following U.S. Executive Order, Supported by Peer-Reviewed Research and Active Programs</title>
<link>https://6ix.com/company/netramark-holdings-inc/news/netramark-positioned-to-advance-psychedelic-clinical-trials-following-us-executive-order-supported-by-peer-reviewed-research-and-active-programs</link>
<guid isPermaLink="true">https://6ix.com/company/netramark-holdings-inc/news/netramark-positioned-to-advance-psychedelic-clinical-trials-following-us-executive-order-supported-by-peer-reviewed-research-and-active-programs</guid>
<pubDate>Wed, 22 Apr 2026 11:00:00 GMT</pubDate>
<description>TORONTO, April 22, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the &#x201C;Company&#x201D;...</description>
</item>
<item>
<title>Netramark Comments on U.S. Executive Order to Accelerate Treatments for Serious Mental Illness and Highlights the Need for Regulatory‑Grade Trial Design in Psychedelic Development</title>
<link>https://6ix.com/company/netramark-holdings-inc/news/netramark-comments-on-us-executive-order-to-accelerate-treatments-for-serious-mental-illness-and-highlights-the-need-for-regulatorygrade-trial-design-in-psychedelic-development</link>
<guid isPermaLink="true">https://6ix.com/company/netramark-holdings-inc/news/netramark-comments-on-us-executive-order-to-accelerate-treatments-for-serious-mental-illness-and-highlights-the-need-for-regulatorygrade-trial-design-in-psychedelic-development</guid>
<pubDate>Mon, 20 Apr 2026 11:00:00 GMT</pubDate>
<description>TORONTO, April 20, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a premier artificial intelligence (AI) company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, today commented on the April 18, 2026 U.S. Executive Order, “Accelerating Medical Treatments for Serious Mental Illness,” which outlines federal actions intended to accelerate research, evidence generation, and a</description>
</item>
<item>
<title>Netramark-Authored, Peer-Reviewed Article Suggests Psychedelics Might Not Only Affect Brain Chemistry, They May Also Involve Quantum-Level Processes Inside the Brain</title>
<link>https://6ix.com/company/netramark-holdings-inc/news/netramark-authored-peer-reviewed-article-suggests-psychedelics-might-not-only-affect-brain-chemistry-they-may-also-involve-quantum-level-processes-inside-the-brain</link>
<guid isPermaLink="true">https://6ix.com/company/netramark-holdings-inc/news/netramark-authored-peer-reviewed-article-suggests-psychedelics-might-not-only-affect-brain-chemistry-they-may-also-involve-quantum-level-processes-inside-the-brain</guid>
<pubDate>Thu, 09 Apr 2026 11:00:00 GMT</pubDate>
<description>Publication strengthens NetraMark's case for biomarker-guided enrichment, individualized response...</description>
</item>
<item>
<title>NetraMark Announces Strategic Oncology Research Collaboration with Fondazione per la Medicina Personalizzata to Analyze Landmark ROME Trial Dataset</title>
<link>https://6ix.com/company/netramark-holdings-inc/news/netramark-announces-strategic-oncology-research-collaboration-with-fondazione-per-la-medicina-personalizzata-to-analyze-landmark-rome-trial-dataset-1</link>
<guid isPermaLink="true">https://6ix.com/company/netramark-holdings-inc/news/netramark-announces-strategic-oncology-research-collaboration-with-fondazione-per-la-medicina-personalizzata-to-analyze-landmark-rome-trial-dataset-1</guid>
<pubDate>Wed, 25 Mar 2026 11:00:00 GMT</pubDate>
<description>TORONTO, March 25, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the &#x201C;Company&#x201D;...</description>
</item>
<item>
<title>NetraMark Unveils AI-Discovered Treatment-Responsive Subgroups in A4 Alzheimer's Trial at AD/PD Conference</title>
<link>https://6ix.com/company/netramark-holdings-inc/news/netramark-unveils-ai-discovered-treatment-responsive-subgroups-in-a4-alzheimers-trial-at-adpd-conference-1</link>
<guid isPermaLink="true">https://6ix.com/company/netramark-holdings-inc/news/netramark-unveils-ai-discovered-treatment-responsive-subgroups-in-a4-alzheimers-trial-at-adpd-conference-1</guid>
<pubDate>Thu, 19 Mar 2026 11:00:00 GMT</pubDate>
<description>TORONTO, March 19, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the &#x201C;Company&#x201...</description>
</item>
<item>
<title>NetraMark Unveils AI-Discovered Treatment-Responsive Subgroups in A4 Alzheimer’s Trial at AD/PD Conference</title>
<link>https://6ix.com/company/netramark-holdings-inc/news/netramark-unveils-ai-discovered-treatment-responsive-subgroups-in-a4-alzheimers-trial-at-adpd-conference-2</link>
<guid isPermaLink="true">https://6ix.com/company/netramark-holdings-inc/news/netramark-unveils-ai-discovered-treatment-responsive-subgroups-in-a4-alzheimers-trial-at-adpd-conference-2</guid>
<pubDate>Thu, 19 Mar 2026 11:00:00 GMT</pubDate>
<description>Results illustrate how NetraMark’s advanced AI can potentially support precision enrichment strategies in future trialsTORONTO, March 19, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a company developing advanced artificial intelligence solutions for clinical trial optimization and precision medicine, today announced new findings illustrating the ability of its proprietary explainable AI platform, NetraAI, to uncover</description>
</item>
<item>
<title>NetraMark Signs Contract With Global Biopharmaceutical Company to Analyze Phase 2 Depression Trial Data</title>
<link>https://6ix.com/company/netramark-holdings-inc/news/netramark-signs-contract-with-global-biopharmaceutical-company-to-analyze-phase-2-depression-trial-data-1</link>
<guid isPermaLink="true">https://6ix.com/company/netramark-holdings-inc/news/netramark-signs-contract-with-global-biopharmaceutical-company-to-analyze-phase-2-depression-trial-data-1</guid>
<pubDate>Wed, 11 Mar 2026 11:00:00 GMT</pubDate>
<description>Agreement further extends NetraMark&#x2019;s portfolio of AI-driven projects in depression and ce...</description>
</item>
<item>
<title>NetraMark Closes Final Tranche of $3.5 Million Private Placement</title>
<link>https://6ix.com/company/netramark-holdings-inc/news/netramark-closes-final-tranche-of-dollar35-million-private-placement-1</link>
<guid isPermaLink="true">https://6ix.com/company/netramark-holdings-inc/news/netramark-closes-final-tranche-of-dollar35-million-private-placement-1</guid>
<pubDate>Thu, 19 Feb 2026 12:00:00 GMT</pubDate>
<description>TORONTO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the &#x201C;Company&#x201D; ...</description>
</item>
</channel>
</rss>